Aptar Pharma and Dianosic discuss their strategic partnership to advance innovative intranasal drug delivery solutions for chronic allergic rhinitis (CAR) and chronic rhinosinusitis (CRS). The interview highlights unmet medical needs, including the limited efficacy of existing treatments and challenges with patient adherence. Dianosic’s “insert and forget” platform is designed to enable targeted and long-acting drug delivery, while Aptar Pharma contributes its expertise in intranasal drug delivery knowledge. The collaboration is progressing toward clinical development and exploring broader therapeutic applications, as well as pharmaceutical partnerships to bring these patient-centric innovations to market.
Following the announcement of Aptar Pharma and Dianosic’s exclusive partnership last year, the interview further introduces the collaboration between the two companies, established to develop innovative intranasal therapies for chronic allergic rhinitis (CAR) and chronic rhinosinusitis (CRS).
Dianosic presents its long‑acting intranasal technology, designed as an “insert and forget” solution that delivers drugs directly to the target site over an extended period. This approach is designed to support sustained drug release and help address patient adherence challenges associated with conventional therapies.
The collaboration combines Aptar Pharma’s expertise in intranasal drug delivery with Dianosic’s unique capabilities, supporting clinical development and co‑development opportunities. Beyond respiratory indications, the platform also shows opportunities for broader applications, including nose‑to‑brain drug delivery.
By bringing together longstanding expertise and market leadership in the nasal drug delivery field with innovative treatment approaches, the collaboration aims to leverage complementary strengths to improve patient outcomes. The partnership reflects the belief that meaningful progress remains possible even within an established market. To support this objective, Aptar Pharma and Dianosic are seeking pharmaceutical collaborators to advance co-development efforts and facilitate the successful introduction of these innovative solutions to market.